16th Feb 2026 15:30
GSK plc (the 'Company')
2026 Awards under the Deferred Investment Award Programme
Notional Award
On 12 February 2026, the Company granted awards over notional Ordinary Shares to Persons Discharging Managerial Responsibilities ('PDMRs') under the GlaxoSmithKline Deferred Investment Award programme.
Under the programme, awards are made over notional Ordinary Shares with vesting over a specified period to provide long-term alignment with shareholders. Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause. No dividends will accrue on the award during the vesting period. On vesting, the award will be paid in cash. Executive Directors are not eligible to receive awards under the programme.
The awards have been granted to reward outstanding performance during 2025 for two newly appointed Executive Committee members as part of the Company's performance system for the general employee population. The awards will vest on 12 February 2029.
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Lynn Baxter | |||
b) | Position/status | President, Europe | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£21.41 | 3,020 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2026-02-12 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mondher Mahjoubi | |||
b) | Position/status | Chief Patient Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£21.41 | 3,020 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2026-02-12 | |||
f) | Place of the transaction
| N/A | |||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
Related Shares:
Glaxosmithkline